News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
The scientists argued that studies indicate the creatine kinase-myocardial band testing has no "incremental value to patient care" and outlined steps to put the test to rest.
The latest offering puts the genetic testing company on the path toward becoming what it calls a preventive health service company.
The firm anticipates receiving regulatory approval from the CFDA for its first three products by the end of the year, including one for lung cancer.
The assay quantitatively measures the biomarker troponin at far lower levels than existing technologies, the company said.
Quidel said that the purchases, expected to close in September, would give it an expanded portfolio of rapid diagnostic capabilities in critical care.
